Microchip Appoints Chief Operating Officer
News Oct 21, 2005
Microchip Biotechnologies Inc. has announced that it has named Dr. Barney E. Saunders as its Chief Operating Officer.
Most recently Dr. Saunders held positions at Agilent Technologies, within their Life Sciences and Chemical Analysis division, as General Manager and Vice President, Bioresearch Solutions, and Senior Director, Science and Technology.
Prior to this Dr. Saunders spent thirteen years at Amersham Biosciences in Europe and North America where he held a variety of commercial and marketing positions.
“I am delighted to have Barney join our team,” said Stevan Jovanovich, President and CEO of MBI.
“His knowledge of the Life Sciences industry and experience in taking breakthrough technologies to market will be of great value as MBI begins to commercialize our NanoBioProcessor™ technology.”
“Microchip Biotechnologies has exceptional technology and a team well- versed in developing cutting edge instrumentation,” said Dr. Saunders.
“I am looking forward to working with Stevan and the rest of MBI's team to bring much needed nanofluidic sample preparation products that will become front- ends to current and future analytical instruments serving the Life Sciences and Biodefense industries.”
Saunders was educated in England and received a Bachelor of Sciences in Biological Sciences and a Ph.D. in Molecular Biology from the University of Birmingham, UK.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.